Business
Milestone Scientific Reports Revenue of $2.2 Million and Provides Business Update for the First Quarter of 2025
Reports Increased CompuFlo® Adoption Following Assignment of Favorable Medicare Payment Rates; Expands Federal Outreach Following FSS Contract AwardROSELAND, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and reported financial results for the first quarter ended March 31, 2025. Neal Goldman, Chairman and Interim Chief Execut
About this update from Milestone Scientific, Inc.
[{"type":"image","alt":"Milestone Scientific, Inc.","displaySize":"","headline":null,"caption":"Milestone Scientific, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/2153125b7314814c812953238fb1ca11"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/exjbRkdU8va83bSGZUweuQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/2153125b7314814c812953238fb1ca11","width":300,"height":65}},"lazy":false},{"type":"text","content":"Reports Increased CompuFlo® Adoption Following Assignment of Favorable Medicare Payment Rates; Expands Federal Outreach Following FSS Contract Award","length":148,"tagName":"p"},{"type":"text","content":"ROSELAND, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and reported financial results for the first quarter ended March 31, 2025.","length":304,"tagName":"p"},{"type":"text","content":"Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, commented, "We are encouraged by the growing momentum in our medical segment, where first quarter results reflect increased traction for the CompuFlo® Epidural System. During the quarter, we were pleased to see new practices integrating CompuFlo into their workflows. These adoptions reflect both the clinical value of our technology and the increasing recognition among pain management specialists of its ability to enhance patient safety and procedural efficiency."","length":561,"tagName":"p"},{"type":"text","content":""Commercially, we remain focused on expanding penetration within existing Jurisdictional Medicare Administrative Contractors (JMACs) and are making measurable progress in our efforts to add new jurisdictions. We are actively engaging with additional JMACs and their advisory networks, and we are optimistic about securing broader regional alignment in the coming quarters. These efforts are supported by the assignment of favorable Medicare Part B physician payment rates for our technology under CPT code 0777T by First Coast Service Options (FCSO) and Novitas Solutions—two key JMACs. We believe this reimbursement framework is a critical c...